Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: ladyPI who wrote (49478)	1/21/2019 11:58:54 AM
From: blessedtobehere	8 Recommendations Recommended By bnutman bobbseytwins2001 captcobra1 dorightbythem drtom1234 and 3 more members Read Replies (1) \| Respond to of 63284

Correct. Neither of us know the details, but you've been leaning toward management being the issue since November when Pehl made his "issues" statement. Based on the evidence, I am very heavily leaning toward a FDA problem and until the FDA and/or IMMU can provide specifics on why a life saving drug cannot be marketed to a group of dying women, I would definitely encourage those women to press for answers. You state, "Unfortunately, there are manufacturing issues that can cause harm to people" Then you turn around and say neither of us know. Well there is one thing I do know. The people who want the drug and can't get the drug are beyond being harmed. They are dying.